Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Shambavi Richard, MD
Articles by Shambavi Richard, MD
Dr. Richard Discusses FDA CAR-T Prescription Label Update Mandate
Shambavi Richard, MD
Transplantation & Cellular Therapy
|
February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
View More
Shambavi Richard, MD, Reflects on National Women Physicians Day
Shambavi Richard, MD
Video Insights
|
February 8, 2024
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
View More
What Is the Future of CART-ddBCMA?
Shambavi Richard, MD
Myeloma
|
July 24, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
View More
Panel Highlights Key Myeloma Takeaways From ASCO 2023
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists highlight key data presented at ASCO 2023.
View More
What Are the Considerations with Toxicity, Access in BCMA-Directed Bispecifics?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
View More
Panel Discusses Use of Bispecifics to Treat Relapsed/Refractory Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
View More
What Are the Novel BCMA-Targeted CAR-T Therapies in the Myeloma Pipeline?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
View More
Real-World CAR-T Outcomes, Use of Ide-Cel, Cilta-Cel for Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
View More
Panelists Discuss Access to CAR-T for Patients with Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
View More
What Is the Role of BCMA-Targeted CAR-Ts in Late-Relapse Multiple Myeloma?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
View More
Panel Discusses Maintenance Therapy, the Changing Landscape for Early-Relapse Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
View More
Early Relapse: Three Versus Four Drugs for Induction in Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
View More
Panel Discusses Best Practices for Post-CAR-T Management with Local Health Care Teams
Thomas Martin, MD
Video Insights
|
May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
View More
Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection
Thomas Martin, MD
Video Insights
|
May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
View More
Bispecific Versus CAR T-Cell Therapy for Myeloma, Bridging Therapy Needs for CAR-T
Thomas Martin, MD
Video Insights
|
May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
View More
Who Is the Right Patient for CAR-T Therapy?
Thomas Martin, MD
Video Insights
|
May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
View More
Frontline CAR-T Use and the 'Sweet Spot' for Treatment Sequencing
Thomas Martin, MD
Video Insights
|
May 5, 2023
The panel addresses the potential for frontline CAR-T use.
View More
Moving CAR-T Therapy Earlier in the Myeloma Treatment Course
Thomas Martin, MD
Video Insights
|
May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
View More
Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
View More
Dual-Targeting, Allogeneic CARs Are Options to ‘Keep Myeloma on its Toes’
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
View More
Load More